SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

NCT02798744 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Empagliflozin
BEHAVIORAL: Diet
DRUG: Placebo

Sponsor

University of Leicester

Collaborators

[object Object]
[object Object]